Medical safety alert

Typhim Vi - Orgaran 750 anti-Xa units solution for injection – incorrect patient information leaflet

(Merck Sharp & Dohme Limited trading as Organon Laboratories Limited) Technical portion of leaflet aimed at the healthcare professional omitted. (EL (12)A/35)

28 November 2012

Class 4 medicines defect information

Caution in use

Distribute to hospital pharmacy level

MDR 29-11/12

Product details

Organon Laboratories Limited

Orgaran 750 anti-Xa units, solution for injection

(Danaparoid sodium)

PL 00065/0125

Alert details

Batch number   Expiry date   Pack size   First distributed
166413001   December 2014   10 ampoules   14 February 2012
222239001   January 2015   10 ampoules   1 March 2012
22224001   January 2015   10 ampoules   10 April 2012
238587001   February 2015   10 ampoules   3 May 2012
296983001   April 2015   10 ampoules   28 June 2012
307099001   July 2015   10 ampoules   10 September 2012
335914001   August 2015   10 ampoules   8 October 2012

Merck Sharp & Dohme Limited (trading as Organon Laboratories Limited) has recently amended the package leaflet for the above product to include user tested text in the patient leaflet section. They have informed us that during this process the previous technical portion of the leaflet aimed at the healthcare professional administering the product has been omitted.

To ensure continuity of supply, distribution of affected stock will continue and it will be necessary to release further batches.

The technical part of this leaflet is the same as the SPC for the product and healthcare professionals needing full instructions for use are referred to the Electronic Medicines Compendium (eMC)  where they can access the latest SPC for Orgaran.

Merck Sharp & Dohme Limited is working to resolve this situation as quickly as possible but it may be a few months before new stock containing both patient and technical leaflets is available.

For further information, please contact Merck Sharp & Dohme Medical Information team on 01992 467272.

Recipients of this drug alert are requested to bring it to the attention of relevant professionals by copy of this letter.

MHRA distribution

Further recipients by cascade:

Regional contacts for NHS Trusts and provider units
Chief Pharmacists: England, Scotland, Wales, Northern Ireland
Prison health policy unit (DH)
Chief Pharmacists: Jersey, Guernsey, Alderney, Sark, Isle of Man, Gibraltar
Special hospitals
Healthcare Commission for distribution to independent health care establishments
Primary care trusts (England)

Download documents

Help us improve GOV.UK

Don't include personal or financial information, eg your National Insurance number or credit card details.